Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04477096
Other study ID # HS-10234-108
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date August 3, 2020
Est. completion date September 24, 2020

Study information

Verified date July 2020
Source Jiangsu Hansoh Pharmaceutical Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is being conducted to evaluate drug interaction between HS-10234 and Emtricitabine after multiple dose in healthy subjects.


Description:

The study includes two parts. Part 1 is to evaluate the impact of Emtricitabine on HS-10234. Part 2 is to evaluate the impact of HS-10234 on Emtricitabine.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date September 24, 2020
Est. primary completion date September 24, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

1. Voluntarily sign an informed consent before any activities related to this trial and understand the procedures and methods of this trial;

2. Aged between 18 and 55 years old (including cutoff value), both male and female;

3. Male body weight =50.0kg, female body weight =45.0kg, body mass index (BMI) is 19~26 kg/m2 (including both ends);

4. Those who signed the informed consent form and had no birth plan within 3 months after the last dose and agreed to take effective contraceptive measures.

Exclusion Criteria:

1. People who have been or are currently suffering from any clinically serious diseases such as circulatory system, endocrine system, nervous system, digestive system, respiratory system, hematology, immunology, psychiatry and metabolic abnormalities, or any other diseases that can interfere with the test results, Or have a stomach problem or have a history of stomach problems;

2. People who have drugs (penicillin or cephalosporin drugs), food, or have a history of allergy to test drugs or similar drugs;

3. If the subject have a history of surgery within the 4 weeks prior to the trial or plan to undergo surgery during the study period or have surgery that affected the absorption, distribution, metabolism, and excretion of drugs;

4. Those who took any prescription drugs, over-the-counter drugs, Chinese herbal medicines or health products within 14 days before taking the study drug, or those who were within 5 half-lives of the drug at the time of screening; those who plan to take non-study drugs or health products during the trial;

5. Those who participated in any drug clinical trial and used any trial drug within 3 months before administration (subject to the informed consent);

6. Participate in blood donation within 3 months before administration and the amount of blood donation >200 mL, or have received blood transfusion;

7. Unable or unwilling to follow the lifestyle guidelines required in the plan;

8. Smokers or those who smoked more than 5 cigarettes per day in the 3 months before the trial;

9. Alcoholics or frequent drinkers within 6 months before the test, that is, drinking more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of 40% alcohol or 150 mL of wine) or before administration Alcohol screening positive;

10. People who have a history of drug abuse, drug dependence, or a positive drug screen before administration;

11. Screening/baseline visit to alanine aminotransferase and/or aspartate aminotransferase and/or alkaline phosphatase and/or total bilirubin exceeds 1.2 times the upper limit of normal;

12. Abnormal vital signs (systolic blood pressure <90 mmHg or >140 mmHg, diastolic blood pressure <50 mmHg or >90 mmHg; pulse <50 bpm or >100 bpm) or physical examination, electrocardiogram, laboratory examination, imaging examination, etc. Abnormality has clinical significance (subject to the judgment of the clinical research doctor);

13. The QT interval is prolonged during screening (calculated using Bazett's method, male>450 msec, female>460 msec);

14. Hepatitis B surface antigen, hepatitis C antibody, syphilis serotonin, HIV antibody test positive;

15. Women during pregnancy or lactation;

16. Subjects may not be able to complete the study for other reasons or the investigator believes that they should not be included.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
HS-10234
HS-10234
Emtricitabine
Emtricitabine

Locations

Country Name City State
China Xiangya Hospital, Central South University Changsha Hunan

Sponsors (1)

Lead Sponsor Collaborator
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pharmacokinetics parameters of HS-10234 and it's metabolite tenofovir, Emtricitabine Cmax 0 - 24 hour on 7th day
Primary Pharmacokinetics parameters of HS-10234 and it's metabolite tenofovir, Emtricitabine AUC0-tau 0 - 24 hour on 7th day
Secondary Concentration of HS-10234's metabolite tenofovir-diphosphate in peripheral blood mononuclear cells. Concentration 0 - 24 hour on 7th day
Secondary Incidence of AEs, laboratory abnormalities (based on hematology, biochemistry, and urinalysis tests) 0 - 23 day
Secondary Incidence of AEs, body temperature 0 - 23 day
Secondary Incidence of AEs, respiratory rate 0 - 23 day
Secondary Incidence of AEs, blood pressure 0 - 23 day
Secondary Incidence of AEs, pulse rate 0 - 23 day
Secondary Incidence of AEs, Resting 12-lead ECG parameters(ECG QT Interval) 0 - 23 day
See also
  Status Clinical Trial Phase
Completed NCT05483998 - A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants Phase 1
Recruiting NCT02417714 - Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
Recruiting NCT02235012 - Cognitive Biases Under Ketamine N/A
Completed NCT04418973 - Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject. N/A
Completed NCT05088343 - Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects Phase 1
Not yet recruiting NCT06248801 - Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets Phase 1
Terminated NCT04068259 - Single Ascending Dose Study of PBI-4547 in Healthy Subjects Phase 1
Completed NCT03279302 - Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects Phase 1
Not yet recruiting NCT06233162 - Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets Phase 1
Recruiting NCT04159844 - Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects N/A
Completed NCT06137911 - Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults. Phase 1
Completed NCT04849286 - Measurement of HTL0016878 in Cerebrospinal Fluid Phase 1
Not yet recruiting NCT06233227 - Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule Phase 1
Completed NCT04096157 - A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants Phase 1
Completed NCT01200368 - Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants Phase 3
Recruiting NCT05805033 - Peri-Implant Soft Tissue Integration in Humans: Influence of Material N/A
Completed NCT04027803 - Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris® Phase 1
Recruiting NCT03467880 - Multicenter Study of Impulse Oscillometry in Chinese N/A
Completed NCT02903095 - Single Ascending Dose Study of TD-1439 in Healthy Subjects Phase 1
Active, not recruiting NCT02341508 - A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers Phase 1